Couverture de Cell Mates

Cell Mates

Cell Mates

De : Multiply Labs
Écouter gratuitement

3 mois pour 0,99 €/mois

Après 3 mois, 9.95 €/mois. Offre soumise à conditions.

À propos de ce contenu audio

Cell Mates is a podcast where we bring together engineers and scientists to tackle the distinct challenges of pharma automation.

By combining engineering expertise with scientific insight, we explore how robotics, automation, and AI are advancing the future of pharmaceutical manufacturing.

Our mission is to foster collaboration across disciplines and highlight the innovations driving forward the future of the pharmaceutical space.

© 2025 Cell Mates
Direction Economie Management et direction Science
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Collaborative Robots for Pharma | Cell Mates E3 feat. Universal Robots
      Nov 3 2025

      What is a collaborative robot, and what makes it special? Why does this characteristic make it suitable for the pharma space?

      In Episode 3 of Cell Mates, we explore how collaborative robotics could redefine manufacturing models, shift the role of human experts, and unlock entirely new possibilities in biomanufacturing.

      Highlights include:

      • What other industries can teach pharma about robotic adoption

      • How to build trust in automation within highly regulated environments

      • The “moonshot projects” that could change everything

      This episode breaks down the future we’re building!

      New to Cell Mates? We’re the podcast where pharma, robotics, and automation collide to reimagine the future of medicine - one operation at a time.

      Afficher plus Afficher moins
      32 min
    • Cell Mates Podcast Ep. 2 | Humanoid Robots and the Future of Biomanufacturing
      Jun 17 2025

      What tasks are humanoids uniquely good at and what does that mean for the future of work?

      In Episode 2 of Cell Mates, we invite Tony Yang, Director of North American Markets from Unitree Robotics to discuss the future of humanoid robots and how robots can fundamentally change the future. We explore in particular what this means for the biomanufacturing industry.

      Highlights include:

      • Where do humanoids fit in pharma?
      • What makes robotic adoption difficult (yet inevitable)?
      • What could a future filled with humanoids could look like?

      This episode breaks down what the robotic future might actually look like, and how close we are to building it!

      New to Cell Mates? We're the podcast where pharma, robotics, and automation collide to reimagine the future of medicine—one operation at a time.

      Afficher plus Afficher moins
      24 min
    • Cell Mates Podcast Ep. 1 | Where Science & Engineering Collide in Pharma Automation
      Feb 20 2025

      What happens when scientists and engineers collaborate to tackle the biggest challenges in pharma manufacturing? In this debut episode, Multiply Labs CEO Frederico Parietti, Ph.D., sits down with Sanket Acharya, Ph.D., Senior Director of Corporate Development at GenScript, to explore the critical intersection of science and automation.


      Key topics we cover:
      ⚙️ What engineers often misunderstand about science
      🔬 What scientists often get wrong about engineering
      🤝 How cross-disciplinary collaboration drives innovation in pharma manufacturing
      🤖 The role of automation and robotics in scaling personalized therapies

      At Multiply Labs, we believe that automation is the future of pharma manufacturing—and that bridging the gap between disciplines is key to unlocking new breakthroughs. Cell Mates brings you candid conversations with industry leaders who are shaping the future of cell and gene therapy manufacturing.


      🎧 Listen to the full episode now and join the conversation! Don’t forget to like, comment, and subscribe to stay updated on future episodes.

      Afficher plus Afficher moins
      22 min
    Aucun commentaire pour le moment